84
Views
1
CrossRef citations to date
0
Altmetric
Original Research

The Prognostic Role and Nomogram Establishment of a Novel Prognostic Score Combining with Fibrinogen and Albumin Levels in Patients with WHO Grade II/III Gliomas

, , , & ORCID Icon
Pages 2137-2145 | Published online: 28 May 2021

References

  • Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62. doi:10.1093/neuonc/nov189
  • Walsh KM, Ohgaki H, Wrensch MR. Epidemiology. Handb Clin Neurol. 2016;134:3–18.
  • Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63. doi:10.1093/neuonc/nou223
  • Abrigo JM, Fountain DM, Provenzale JM, et al. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. Cochrane Database Syst Rev. 2018;1:CD011551. doi:10.1002/14651858.CD011551.pub2
  • Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215–219. doi:10.1093/jnen/61.3.215
  • Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–397.
  • Ding H, Huang Y, Li Z, et al. Prediction of IDH status through MRI features and enlightened reflection on the delineation of target volume in low-grade gliomas. Technol Cancer Res Treat. 2019;18:1533033819877167. doi:10.1177/1533033819877167
  • Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10(3):224–231. doi:10.1007/s11910-010-0105-7
  • Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G; Group EGW. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii93–101. doi:10.1093/annonc/mdu050
  • Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–1030. doi:10.1038/sj.bjc.6601242
  • Matsuda S, Takeuchi H, Kawakubo H, et al. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol. 2015;22(1):302–310. doi:10.1245/s10434-014-3857-5
  • He ZQ, Ke C, Al-Nahari F, et al. Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas. J Neurooncol. 2017;132(2):239–247. doi:10.1007/s11060-016-2361-0
  • Chan DY, Syn NL, Yap R, et al. Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. are we ready? J Gastrointest Surg. 2017;21(3):425–433. doi:10.1007/s11605-016-3336-3
  • Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
  • Qureshi YA, Sarker SJ, Walker RC, Hughes SF. Proximal resection margin in ivor-lewis oesophagectomy for cancer. Ann Surg Oncol. 2017;24(2):569–577. doi:10.1245/s10434-016-5510-y
  • Gan Y, Zhou X, Niu X, et al. Neutrophil/lymphocyte ratio is an independent prognostic factor in elderly patients with high-grade gliomas. World Neurosurg. 2019;127:e261–e267. doi:10.1016/j.wneu.2019.03.085
  • Armocida D, Pesce A, Di Giammarco F, Frati A, Santoro A, Salvati M. Long term survival in patients suffering from glio-blastoma multiforme: a single-center observational cohort study. Diagnostics (Basel). 2019;9(4). doi:10.3390/diagnostics9040209
  • Dietterle J, Wende T, Wilhelmy F, et al. The prognostic value of peri-operative neurological performance in glioblastoma patients. Acta Neurochir (Wien). 2019;162:417–425. doi:10.1007/s00701-019-04136-4
  • Marques C, Carvelli J, Biard L, et al. Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients. Front Immunol. 2019;10:1665. doi:10.3389/fimmu.2019.01665
  • Picca A, Berzero G, Sanson M. Current therapeutic approaches to diffuse grade II and III gliomas. Ther Adv Neurol Disord. 2018;11:1756285617752039. doi:10.1177/1756285617752039
  • Seystahl K, Wiestler B, Hundsberger T, et al. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol. 2013;69(2):95–101. doi:10.1159/000343811
  • Chen S, Yan H, Du J, et al. Prognostic significance of pre-resection albumin/fibrinogen ratio in patients with non-small cell lung cancer: a propensity score matching analysis. Clin Chim Acta. 2018;482:203–208. doi:10.1016/j.cca.2018.04.012
  • Liang Y, Wang W, Que Y, et al. Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma. BMC Cancer. 2018;18(1):942. doi:10.1186/s12885-018-4856-x
  • Wang Y, Chen W, Hu C, et al. Albumin and fibrinogen combined prognostic grade predicts prognosis of patients with prostate cancer. J Cancer. 2017;8(19):3992–4001. doi:10.7150/jca.21061
  • Li SQ, Jiang YH, Lin J, et al. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals. Cancer Med. 2018;7(4):1221–1231. doi:10.1002/cam4.1428
  • Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019;19(1):288. doi:10.1186/s12885-019-5490-y
  • Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci. 2001;936:406–425. doi:10.1111/j.1749-6632.2001.tb03525.x
  • Gulen ST, Karadag F, Karul AB, et al. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung. 2012;190(3):327–332. doi:10.1007/s00408-011-9364-6
  • Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178–185. doi:10.1182/blood-2004-06-2272
  • Esmon CT. Does inflammation contribute to thrombotic events? Haemostasis. 2000;30(Suppl 2):34–40. doi:10.1159/000054161
  • Dolan RD, Laird BJA, Klepstad P, et al. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine (Baltimore). 2019;98(37):e17019. doi:10.1097/MD.0000000000017019
  • Xu Q, Yan Y, Gu S, et al. A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma. J Immunol Res. 2018;2018:4925498. doi:10.1155/2018/4925498
  • Wang PF, Meng Z, Song HW, et al. Preoperative changes in hematological markers and predictors of glioma grade and survival. Front Pharmacol. 2018;9:886. doi:10.3389/fphar.2018.00886
  • Han S, Huang Y, Li Z, Hou H, Wu A. The prognostic role of preoperative serum albumin levels in glioblastoma patients. BMC Cancer. 2015;15:108. doi:10.1186/s12885-015-1125-0
  • Reynes G, Vila V, Martin M, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2011;102(1):35–41. doi:10.1007/s11060-010-0290-x
  • Loeffler S, Fayard B, Weis J, Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 2005;115(2):202–213. doi:10.1002/ijc.20871
  • Albrecht U, Yang X, Asselta R, et al. Activation of NF-kappaB by IL-1beta blocks IL-6-induced sustained STAT3 activation and STAT3-dependent gene expression of the human gamma-fibrinogen gene. Cell Signal. 2007;19(9):1866–1878. doi:10.1016/j.cellsig.2007.04.007
  • Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385–401. doi:10.1002/hep.1840080234
  • Li SQ, You XH, Sun F, et al. Albumin to fibrinogen ratio and fibrinogen to pre-albumin ratio are economical, simple and promising prognostic factors for solid malignancy. J Thorac Dis. 2019;11(Suppl 15):S2036–S2038. doi:10.21037/jtd.2019.08.96
  • Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
  • Wang J, Qu J, Li Z, et al. A prognostic model in metastatic or recurrent gastric cancer patients with good performance status who received first-line chemotherapy. Transl Oncol. 2016;9(3):256–261. doi:10.1016/j.tranon.2016.04.004
  • Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350. doi:10.1186/1471-2407-13-350
  • Xin-Ji Z, Yong-Gang L, Xiao-Jun S, Xiao-Wu C, Dong Z, Da-jian Z. The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: a meta-analysis. Int J Surg. 2015;21:84–91. doi:10.1016/j.ijsu.2015.07.681
  • Wang J, Qu J, Li Z, et al. Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer. J Clin Lab Anal. 2018;32(1):e22185. doi:10.1002/jcla.22185
  • Wang DP, Kang K, Lin Q, Hai J. Prognostic significance of preoperative systemic cellular inflammatory markers in gliomas: a systematic review and meta-analysis. Clin Transl Sci. 2019;13:179–188. doi:10.1111/cts.12700
  • Yang T, Mao P, Chen X, et al. Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram. Oncol Lett. 2019;17(2):2516–2522. doi:10.3892/ol.2018.9870
  • Madsen LT. Cancer prediction nomograms for advanced practitioners in oncology. J Adv Pract Oncol. 2014;5(5):380–382.
  • Giordano A, Egleston BL, Hajage D, et al. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res. 2013;19(6):1596–1602. doi:10.1158/1078-0432.CCR-12-3137